KAI-WEN HUANGYang P.-C.Pua U.Kim M.-D.Li S.-P.Qiu Y.-D.Song T.-Q.PO-CHIN LIANG2020-06-192020-06-1920180022-4790https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053238357&doi=10.1002%2fjso.25110&partnerID=40&md5=04e52389c5b148f3509e3c7d1721973fhttps://scholars.lib.ntu.edu.tw/handle/123456789/503603Background and Objectives: Irreversible electroporation (IRE) is a non-thermal focal therapy that utilizes high voltage electric pulses to permanently rupture the cellular membrane and induce cell death. In this multi-center study, we evaluated the safety and efficacy of IRE in patients with locally advanced pancreatic cancer (LAPC). Methods: From 2012 to 2015, we performed laparotomic and laparoscopic IRE in a total of 70 patients with stage III LAPC. Either gemcitabine-based or TS-1 (Tegafur, Gimeracil, and Oteracil) chemotherapy was applied for at least 3 months before the IRE. Results: No IRE-related deaths occurred. A median follow-up of 28.1 months showed that six patients (8.6%) experienced local recurrence and 24 (34%) experienced distant progression. The overall median survival from the time of treatment was 22.6 months, and the progression-free survival (PFS) was 15.4 months. The overall survival in the patients who used gemcitabine-based reagents was 19.1 months and that of those who used TS-1 was 28.7 months. The PFS for these two groups were 13.2 months and 26.4 months; the difference is significant. Conclusions: Our study suggests that IRE is safe and effective for the control of LAPC. We surmise that the addition of IRE to a chemotherapy regimen may provide a survival advantage. ? 2018 Wiley Periodicals, Inc.[SDGs]SDG3gemcitabine; gimeracil plus oteracil potassium plus tegafur; antineoplastic agent; deoxycytidine; fluorouracil; gemcitabine; oteracil; pyridine derivative; tegafur; tegafur-gimeracil-oteracil; abdominal abscess; acute hepatitis; advanced cancer; Article; ascites; cancer combination chemotherapy; cancer patient; cancer recurrence; cancer surgery; cancer survival; clinical trial; false aneurysm; follow up; gastrointestinal hemorrhage; human; induction chemotherapy; irreversible electroporation; laparoscopic surgery; laparotomy; major clinical study; median survival time; multiple cycle treatment; overall survival; pancreas adenocarcinoma; pancreas fistula; patient safety; postoperative complication; postoperative hemorrhage; postoperative ileus; priority journal; progression free survival; prospective study; pseudoaneurysm bleeding; survival rate; therapy effect; adenocarcinoma; adjuvant chemotherapy; analogs and derivatives; catheter ablation; disease free survival; drug combination; electrochemotherapy; induction chemotherapy; pancreas tumor; procedures; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Electrochemotherapy; Fluorouracil; Humans; Induction Chemotherapy; Laparotomy; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Survival Rate; Tegafurjournal article10.1002/jso.25110298783782-s2.0-85053238357